飞鹤上半年营收91.5亿元 净利10.3亿元

Core Insights - China Feihe (6186.HK) reported a mid-year performance for 2025, achieving a revenue of 9.15 billion RMB and a net profit of 1.03 billion RMB, with a strong cash flow of 6.48 billion RMB, indicating robust operational fundamentals and financial resilience [1] - The company maintained its leading market share and sales in the infant formula sector during the reporting period [1] - Feihe's innovation strategy is driven by hard technology, introducing "Fresh Protein Extraction Technology" and the first comprehensive HMOs database in China, reinforcing its technological barriers [1] - The internationalization strategy has accelerated, with over 1,500 supermarkets in North America and a 270% year-on-year increase in overseas store numbers, alongside successful market entry into the Philippines [1] - The company plans to invest 1 billion RMB in share buybacks and distribute approximately 1 billion RMB in interim dividends, with an expected total dividend distribution of no less than 2 billion RMB for 2025, demonstrating commitment to returning value to investors [1] - Feihe has initiated a 1.2 billion RMB fertility subsidy plan, aiming to benefit over 800,000 newborn families, aligning with national policies and emphasizing its social responsibility as a market leader [1]